Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

673
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
673
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

630
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
630
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

489
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
489
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

527
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
527
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

642
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
642
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

614
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
614

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time required to determine performance variables and production efficiency of lactating dairy cows.

Journal of dairy science·2014
Same author

Hypotension during gradual blood loss: waveform variables response and absence of tachycardia.

British journal of anaesthesia·2012
Same author

Outcome and complications of colonoscopy: a prospective multicenter study in northern Israel.

Diagnostic and therapeutic endoscopy·2012
Same author

Prenatal diagnosis of a pulmonary arteriovenous malformation.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2011
Same author

Dimensions of the fetal facial profile in normal pregnancy.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2009
Same author

In vitro fertilisation and use of ovulation enhancers may both influence childhood height in very low birthweight infants.

Archives of disease in childhood. Fetal and neonatal edition·2009
Same journal

Cardiac Imaging Predictors of Ventricular Recovery in Pediatric Patients Undergoing Aortic Valve Intervention for Regurgitation.

Pediatric cardiology·2026
Same journal

Holter-Based Heart Rate Variability Distinguishes Adolescent Postural Orthostatic Tachycardia Syndrome from Healthy Controls.

Pediatric cardiology·2026
Same journal

Left Atrial Function in Children with Cancer Prior to Start of Chemotherapy: A Speckle Echocardiography Analysis.

Pediatric cardiology·2026
Same journal

Early Improvement in Cardiac Autonomic Modulation After a Recreational Physical Training Program in Healthy Children.

Pediatric cardiology·2026
Same journal

Beyond Body Mass Index: Skeletal Muscle Mass as a Marker of Physiologic Reserve in Fontan Circulation.

Pediatric cardiology·2026
Same journal

Geographical and Language-Based Factors Associated with Neurodevelopmental Follow-Up in Children with Congenital Heart Disease.

Pediatric cardiology·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

808

Persistent Pulmonary Hypertension and Histologic Chorioamnionitis in Preterm Infants: Controlled Study.

N Katz1,2,3, Y Bar-Or4, A Raucher-Sterrnfeld5

  • 1Neonatal Intensive Care Unit, Wolfson Medical Center, Holon, Israel. Kneri@WMC.gov.il.

Pediatric Cardiology
|February 18, 2018
PubMed
Summary
This summary is machine-generated.

This study found no association between histologic chorioamnionitis and persistent pulmonary hypertension of the newborn (PPHN) in preterm infants. Further research is needed to understand PPHN causes in this vulnerable population.

Keywords:
Histologic chorioamnionitisPreterm newbornPulmonary hypertension

More Related Videos

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

977
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

670

Related Experiment Videos

Last Updated: Feb 14, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

808
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

977
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

670

Area of Science:

  • Neonatal Medicine
  • Perinatal Pathology

Background:

  • Persistent pulmonary hypertension of the newborn (PPHN) is a critical condition with high morbidity and mortality.
  • Understanding the etiology of PPHN in preterm infants is crucial for improving outcomes.

Purpose of the Study:

  • To investigate the potential association between histologic chorioamnionitis (HCA) and the incidence of echocardiographically confirmed PPHN in preterm infants.
  • To identify risk factors contributing to PPHN in this specific patient group.

Main Methods:

  • A case-control study involving 27 preterm infants with PPHN and 27 matched controls.
  • Data collected included respiratory support, oxygen supplementation, duration of membrane rupture, and maternal/neonatal clinical data.
  • Placental examination for HCA and statistical analysis using t-tests, Kolmogorov-Smirnov, and Chi-square tests.

Main Results:

  • No statistically significant differences were observed between the PPHN and control groups in most parameters.
  • The PPHN group showed a higher utilization of oxygen supplementation.
  • No association was found between HCA and PPHN in preterm infants within the first three days of life.

Conclusions:

  • Histologic chorioamnionitis does not appear to be a significant factor in the development of PPHN in preterm infants within the first three days of life.
  • The underlying causes of PPHN in this population require further investigation.
  • Oxygen supplementation was a notable difference in PPHN management.